We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
08:00
-
Gebre Hall60 mins
- Investment Summit
Registration Sponsored by Catalent
09:00
-
Theatre 1&2 (Rubi & Zafir)15 mins
- Investment Summit
Setting the context, where the CGT investment landscape stands in 2026, what has changed and what it means for European therapeutic developers today Where are we in the market cycle? interpreting reco ...
09:15
-
Theatre 1&2 (Rubi & Zafir)40 mins
- Investment Summit
Story-driven investing is over, what does evidence driven investing actually demand from founders? From narrative to proof: why scientific promise alone no longer closes rounds, and what constitutes a ...
09:55
-
Theatre 1&2 (Rubi & Zafir)40 mins
- Investment Summit
Traditional venture capital is growing more selective and early-stage biotech are sourcing other routes of funding to progress their pipelines. Explore how alternative funding models are evolving to s ...
10:35
-
Workshop Room (Rossini 1&2)30 mins
- Investment Summit
11:05
-
Theatre 1&2 (Rubi & Zafir)40 mins
- Investment Summit
As the cell and gene therapy industry becomes increasingly crowded, differentiation has become a non-negotiable for securing investment. With multiple companies pursuing similar approaches, investors ...
11:45
-
Theatre 1&2 (Rubi & Zafir)30 mins
- Investment Summit
Bringing together investor and founder who have successfully navigated the process to share practical insights on what it takes to secure capital in today’s environment. The 2026 investment checklist: ...
12:15
-
Workshop Room (Rossini 1&2)60 mins
- Investment Summit
- Women in Advanced Therapies Congress
13:15
-
Workshop Room (Rossini 1&2)5 mins
- Women in Advanced Therapies Congress
13:20
-
Workshop Room (Rossini 1&2)20 mins
- Women in Advanced Therapies Congress
13:40
-
Workshop Room (Rossini 1&2)30 mins
- Women in Advanced Therapies Congress
After years of discussion around bias, barriers, and representation, the question remains: what is actually changing and what isn’t? This candid opening session sets the tone for WiAT by shifting the ...Speakers
14:10
-
Workshop Room (Rossini 1&2)35 mins
- Women in Advanced Therapies Congress
What does success actually look like and how do you get there? In this session, leaders share honest, experience-based insights into building careers, securing investment, and navigating pivotal trans ...
14:45
-
Workshop Room (Rossini 1&2)30 mins
- Women in Advanced Therapies Congress
15:15
-
Vivaldi 1&260 mins
- Women in Advanced Therapies Congress
- Roundtable
In Partnership with Advantera -
Vivaldi 1&260 mins
- Women in Advanced Therapies Congress
- Roundtable
Focus: progression into senior roles in pharma, biotech, and startups -
Vivaldi 1&260 mins
- Women in Advanced Therapies Congress
- Roundtable
Focus: the operational reality of building companies and careers in CGT/biotech -
Vivaldi 1&260 mins
- Women in Advanced Therapies Congress
- Roundtable
Focus: refine how you present your experience, expertise, and ambition -
Vivaldi 1&260 mins
- Women in Advanced Therapies Congress
- Roundtable
In Partnership with Fresenius -
Vivaldi 1&260 mins
- Women in Advanced Therapies Congress
- Roundtable
-
Theatre 1&2 (Rubi & Zafir)60 mins
- Women in Advanced Therapies Congress
In Partnership with CGT Circle -
Vivaldi 1&260 mins
- Women in Advanced Therapies Congress
- Roundtable
-
Vivaldi 1&260 mins
- Women in Advanced Therapies Congress
- Roundtable
16:15
-
Workshop Room (Rossini 1&2)15 mins
- Women in Advanced Therapies Congress
18:30
-
Superlocal90 mins
- Networking Break
Join our annual kick-off welcome party taking place at sunset along Barcelona beach! Sponsored by Gift of Life Biologics
08:00
-
Gebre Hall60 mins
- Networking Break
Registration Sponsored by Catalent
09:00
-
Theatre 1&2 (Rubi & Zafir)5 mins
- Plenary
09:05
-
Theatre 1&2 (Rubi & Zafir)10 mins
- Plenary
09:15
-
Theatre 1&2 (Rubi & Zafir)35 mins
- Plenary
From legislation to execution: What ATMP developers must change now in regulatory, CMC and evidence planning to stay aligned with EU reform over the next 12 months. Fixing fragmentation where it hurts ...
09:50
-
Theatre 1&2 (Rubi & Zafir)40 mins
- Plenary
Speed breaks first: Why Europe still loses ATMP programmes at the trial-start and scale-up stages and what can be fixed in the next 12 months around approvals, site readiness and cross-border trial ex ...Speakers
10:30
-
Exhibition Hall45 mins
- Networking Break
11:15
-
Theatre 1 (Zafir)30 mins
- Cell & Gene Therapy Clinical Pathways
Efficacy data as a scaling input, not an endpoint: How Phase I expansion and Phase II data should actively inform tech transfer, manufacturing readiness and comparability so scale-up and fundraising d ... -
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
-
Workshop Room (Rossini 1&2)60 mins
- Workshop
Sponsored by Dark Horse Consulting. Content coming soon.
11:30
-
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
11:45
-
Theatre 1 (Zafir)15 mins
- Cell & Gene Therapy Clinical Pathways
-
Theatre 2 (Rubi)30 mins
- Operational & Commercial Performance
12:00
-
Theatre 1 (Zafir)15 mins
- Cell & Gene Therapy Clinical Pathways
12:15
-
Theatre 1 (Zafir)30 mins
- Cell & Gene Therapy Clinical Pathways
A view on the latest clinical trials, innovations and trends coming out of Europe, US and further afield and what practical coordination would make cross-border trials, faster, simpler and more attrac ... -
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
Cost isn’t just efficiency it’s architecture: How advanced facilities change the cost curve of CGT production, from automation and digitalisation to scale, standardisation and multi-product flexibilit ...
12:30
-
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
CAR-T has delivered transformative clinical outcomes, but its manufacturing model still resembles the early biologics era: complex, bespoke, variable and difficult to scale economically. Antibodies be ...
12:45
-
Exhibition Hall75 mins
- Networking Break
13:00
-
Panel: Designing advanced therapies that survive scale: from early decisions to commercial readinessWorkshop Room (Rossini 1&2)60 mins
- Workshop
Advanced therapy developers face intense pressure to accelerate timelines, but speed without early discipline across CMC, delivery, analytics, and manufacturing can introduce risks that surface later ...
14:00
-
Theatre 1 (Zafir)15 mins
- Cell & Gene Therapy Clinical Pathways
-
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
Scaling MSC manufacturing remains a major challenge in cell therapy development, particularly as processes move from early research into clinical and commercial production. This presentation reviews f ...
14:15
-
Theatre 1 (Zafir)15 mins
- Cell & Gene Therapy Clinical Pathways
The uncomfortable truth: Where early CMC and manufacturing assumptions quietly inflated cost of goods as programmes moved toward later-stage development and why these issues only surfaced under scale ... -
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
14:30
-
Theatre 1 (Zafir)30 mins
- Cell & Gene Therapy Clinical Pathways
AAV demand has outpaced infrastructure: Why current production models struggle to meet clinical and commercial demand and which upstream, downstream and process innovations are finally closing the eff ... -
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
Speakers
14:45
-
Theatre 2 (Rubi)45 mins
- Operational & Commercial Performance
Session Overview Advanced therapies are stretching not just science and regulation but the very design of capital itself. Across Europe, a growing sentiment has emerged that traditional venture capita ...
15:00
-
Theatre 1 (Zafir)15 mins
- Cell & Gene Therapy Clinical Pathways
15:15
-
Theatre 1 (Zafir)45 mins
- Cell & Gene Therapy Clinical Pathways
The inflection is measurable: What recent in vivo clinical readouts are showing about delivery efficiency, expression control and safety—and where performance is becoming reproducible rather than exce ...
15:30
-
Theatre 2 (Rubi)30 mins
- Operational & Commercial Performance
16:00
-
Exhibition Hall30 mins
- Networking Break
16:30
-
Workshop Room (Rossini 1&2)60 mins
- Roundtable
-
Theatre 1&2 (Ruby & Zafir)60 mins
- Roundtable
Chairperson -
Workshop Room (Rossini 1&2)60 mins
- Roundtable
Chairperson -
Workshop Room (Rossini 1&2)60 mins
- Roundtable
-
Workshop Room (Rossini 1&2)60 mins
- Roundtable
-
Workshop Room (Rossini 1&2)60 mins
- Roundtable
Chairperson -
Workshop Room (Rossini 1&2)60 mins
- Roundtable
Chairperson -
Workshop Room (Rossini 1&2)60 mins
- Roundtable
-
Workshop Room (Rossini 1&2)60 mins
- Roundtable
-
Workshop Room (Rossini 1&2)60 mins
- Roundtable
17:30
-
Exhibition Hall105 mins
- Networking Break
09:00
-
Theatre 1 (Zafir)90 mins
- Plenary
Join us for an exciting session where innovative biotech start-ups pitch their groundbreaking ideas and solutions. Watch as they present to a panel of expert investors, who will provide real-time feed ...
10:30
-
Theatre 1 (Zafir)45 mins
- Plenary
From optional to inevitable: Where agentic and analytical AI are already changing discovery and early CGT development and what must be true for AI to become a trusted, default tool rather than a pilot ...Speakers
11:15
-
Exhibition Hall30 mins
- Networking Break
11:45
-
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
Capacity solved, complexity exposed: Why increasing CGT manufacturing capacity alone doesn’t unlock commercial success and how variability, flexibility and operational friction now limit real-world ad ... -
Theatre 1 (Zafir)15 mins
- Cell & Gene Therapy Clinical Pathways
12:00
-
Theatre 1 (Zafir)15 mins
- Cell & Gene Therapy Clinical Pathways
Speakers -
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
12:15
-
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
-
Theatre 1 (Zafir)15 mins
- Cell & Gene Therapy Clinical Pathways
12:30
-
Theatre 1 (Zafir)15 mins
- Cell & Gene Therapy Clinical Pathways
12:45
-
Theatre 1 (Zafir)45 mins
- Cell & Gene Therapy Clinical Pathways
Understanding the AGORA model:How collaborative, hospital-anchored models like AGORA are reshaping access to gene and cell therapies for rare and ultra-rare diseases. We cannot scale without hospitals ...Speakers -
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
Why COGS stays stubbornly high: The recurring technical and operational drivers of cost across CGT programme from starting materials and batch failure rates to logistics and facility utilisation. Wher ...
13:00
-
Theatre 2 (Rubi)30 mins
- Operational & Commercial Performance
The cost equation is breaking :Are allogeneic therapies genuinely approaching a manufacturing inflection point and if so, what does that mean for the long-term viability of autologous models that stil ...
13:30
-
Exhibition Hall75 mins
- Networking Break
-
Workshop Room (Rossini 1&2)60 mins
- Workshop
Join VIVEbiotech together with its partners Kiji Therapeutics and Genewity for an interactive panel exploring how lentiviral vector-based therapies are advancing across the full development pathway—fr ...
)
14:45
-
Theatre 1 (Zafir)5 mins
- Plenary
14:50
-
Theatre 1 (Zafir)15 mins
- Plenary
15:05
-
Theatre 1 (Zafir)20 mins
- Plenary
What it takes to build a decentralised CAR-T manufacturing model in practice, and where the original “point-of-care” vision met operational reality. Key lessons from running multi-site GMP manufacturi ...
15:25
-
Theatre 1 (Zafir)40 mins
- Plenary
The next modality frontier is not guaranteed: Which modalities are genuinely emerging as the next growth engines, whether cell therapies face structural headwinds or reinvention, and what lessons Euro ...